SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 3/27/2017 1:24:17 AM - Followers: 712 - Board type: Free - Posts Today: 7

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  [email protected]
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

FDA Designations:
 


Upcoming Milestones:
 


Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
[email protected]
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  [email protected]

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Current Report Filing (8-k) 02/16/2017 07:01:38 AM
CTIX News: Quarterly Report (10-q) 02/09/2017 04:04:17 PM
CTIX News: Current Report Filing (8-k) 02/09/2017 09:39:24 AM
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
PostSubject
#175917  Sticky Note Cellceutix Releases Favorable Topline Findings as Part of TheHound 03/21/17 08:05:02 AM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#175464  Sticky Note Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as NotAsBigKahuna 03/16/17 09:18:07 AM
#175150  Sticky Note NEAR TERM Certainly plenty of catalysts in the BooDog 03/14/17 06:16:45 AM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#173773  Sticky Note New $CTIX abstract out on Kevetrin ---- > TheHound 03/02/17 08:59:08 AM
#176363   Actually my due diligence is based on the sox040713 03/27/17 01:24:17 AM
#176362   The message you're responding to is one of TheHound 03/27/17 01:24:17 AM
#176361   Sorry I should've provided the links. sox040713 03/27/17 12:58:14 AM
#176360   Done. Leo is keeping me busy. ;-) sox040713 03/27/17 12:52:34 AM
#176359   B-UP Due Diligence (Rev. 3/26) sox040713 03/27/17 12:48:32 AM
#176358   Yes analysts predict SP, but they don't predict sox040713 03/27/17 12:46:10 AM
#176357   Please show me a PR from four years sox040713 03/27/17 12:28:55 AM
#176356   Brilacidin for prevention and treatment of oral mucositis georgejjl 03/26/17 10:34:26 PM
#176352   Remember these days? Will they return? Follow the TheDane 03/26/17 09:30:45 PM
#176351   Just your typical blind hope and faith. scottsmith 03/26/17 08:30:59 PM
#176350   scotts care to share why you feel JTORENCE 03/26/17 08:08:41 PM
#176349   Adam F also calls himself the Colonel Jessup scottsmith 03/26/17 07:41:34 PM
#176348   Data does not lie. faraifarai 03/26/17 07:11:09 PM
#176347   Tomorrow we all get richer. New days scottsmith 03/26/17 06:55:53 PM
#176346   the topic of our discussion was K and TheHound 03/26/17 05:36:59 PM
#176345   Yes actually that shows how market views the Amatuer17 03/26/17 05:19:25 PM
#176343   nope. pointing to our market cap doesn't support TheHound 03/26/17 03:52:23 PM
#176342   Everyone losing market cap here for 2.5 years scottsmith 03/26/17 03:31:55 PM
#176341   Good. Didn't see a "first patient" pr. Did noretreat 03/26/17 03:22:54 PM
#176340   Market is reaching same conclusion and keeping this Amatuer17 03/26/17 03:20:18 PM
#176339   Recruiting already.... https://clinicaltrials.gov/ct2/show/NCT03042702?term=Kev F1ash 03/26/17 03:19:08 PM
#176338   Seems the POC trial has started recruitment as Amatuer17 03/26/17 03:18:30 PM
#176337   The price has been pretty flat this year. noretreat 03/26/17 03:16:05 PM
#176336   When does the ovarian trial start? noretreat 03/26/17 03:12:44 PM
#176335   Weaker price action is your clarion cry, day Blue Fin 03/26/17 03:11:18 PM
#176334   i expect further price weakness this week MXAMDUD 03/26/17 03:06:09 PM
#176333   "believe me"-not in a million years winnail 03/26/17 02:31:58 PM
#176332   positive B-OM interim analysis report TheHound 03/26/17 01:37:14 PM
#176331   Any updates are expected this week ?... anyone ? Vlady 1 03/26/17 01:34:19 PM
#176330   sorry bud but misinformation, half-truths, and speculation don't TheHound 03/26/17 01:29:37 PM
#176329   Actually it is right conclusion. In 2013 - PFE Amatuer17 03/26/17 01:24:44 PM
#176328   Believe me, i don't think many investors do. TheHound 03/26/17 01:23:08 PM
#176327   A Data Monitoring Committee is a group of F1ash 03/26/17 01:06:44 PM
#176326   Believe me, Leo would take any deal now Rdunn88 03/26/17 01:04:20 PM
#176325   "...this clinical trial, using IV dosing, will F1ash 03/26/17 01:02:06 PM
#176324   Great chance the changes were a result of TheHound 03/26/17 12:55:13 PM
#176323   Very poor conclusion amateur. TheHound 03/26/17 12:49:17 PM
#176322   3221 / 22 - Kevetrin induces p53-dependent and georgejjl 03/26/17 10:27:38 AM
#176320   Interim results for Brilacidin OM and Prurisol SOON!!! georgejjl 03/26/17 10:17:51 AM
#176319   Interesting point. I do wonder if Leo is stevo99 03/26/17 09:55:04 AM
#176318   No possibility that CTIX wants to wait until Blue Fin 03/26/17 09:52:00 AM
#176317   aprea-246? You mean that IV drug in a combination runninggirl2016 03/26/17 09:45:29 AM
#176316   There has been talks about how great K Amatuer17 03/26/17 09:38:45 AM
#176315   Your value judgement as drug development being a 58nout 03/26/17 09:32:23 AM
#176314   Brilacidin for prevention and treatment of oral mucositis georgejjl 03/26/17 09:12:00 AM
#176313   keeping an eye on the competition: aprea announces To infinity and beyond! 03/26/17 08:42:52 AM
#176312   Perhaps requested by BP in partnership negotiations? baytdr 03/26/17 03:41:08 AM
#176311   From where you got this information? Which study confirmed this? Amatuer17 03/25/17 09:46:11 PM
#176310   NABK, it might help to expand the XML FlashingLeather 03/25/17 09:29:54 PM
#176309   Phase 2 Study to Evaluate the Efficacy & georgejjl 03/25/17 09:10:03 PM
PostSubject